Effects of enhanced cerebrospinal fluid levels of vasopressin, vasopressin antagonist or vasoactive intestinal polypeptide on circadian sleep-wake rhythm in the rat.
Several endogenous peptides have been implicated in the regulation of sleep and wakefulness. The present study was carried out in order to determine whether the light-dark rhythm of vasopressin (VP) in the cerebrospinal fluid (CSF) had functional significance in relaying information from the circadian pacemaker, i.e. the suprachiasmatic nuclei (which synthesize VP as well as vasoactive intestinal polypeptide (VIP], to the centra regulating sleep. After constant delivery of VP in the CSF via an Accurel/collodion implant in the lateral ventricle, the VP CSF level was raised from 20-35 pg/ml to ca. 265 pg/ml whereby a VP rhythm in the CSF could no longer be detected. Under these conditions VP was found to increase the arousal state of the rat in the dark period, which resulted in a higher amplitude of the circadian sleep-wake rhythm. Application of the VP antagonist d(CH2)5[Tyr(Me)2]VP partly had opposite effects. A similar approach with central application of VIP resulted in an increase in rapid eye movement and quiet sleep but did not affect the amplitude of the circadian rhythm. It was concluded that although peptide levels in the CSF may show clear temporal variations with the light-dark cycle, this rhythmicity is not causally related to the circadian aspect of sleep-wakefulness. However, both VP and VIP contribute to the regulation of the amount of time spent in sleep and wakefulness and the level of VP in the CSF is correlated with the amplitude of the rhythm.
Kruisbrink
J
J
Netherlands Institute for Brain Research, Amsterdam.
Mirmiran
M
M
Van der Woude
T P
TP
Boer
G J
GJ
D000818:Animals; D001127:Arginine Vasopressin / Q000031:analogs & derivatives* / Q000134:cerebrospinal fluid / Q000494:pharmacology; D001921:Brain / Q000187:drug effects / Q000502:physiology; D002940:Circadian Rhythm / Q000187:drug effects*; D007276:Injections, Intraventricular; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012890:Sleep / Q000187:drug effects*; D013997:Time Factors; D014660:Vasoactive Intestinal Peptide / Q000134:cerebrospinal fluid* / Q000502:physiology; D014667:Vasopressins / Q000037:antagonists & inhibitors / Q000134:cerebrospinal fluid* / Q000502:physiology; D014851:Wakefulness / Q000187:drug effects*
D014667:Vasopressins; D001127:Arginine Vasopressin; D014660:Vasoactive Intestinal Peptide; C025043:vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-